Postdoctoral Researcher
Institute for Immunology, Perelman School of Medicine, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Dr. Yuki Muroyama is a MD, PhD immunologist, currently at the University of Pennsylvania, Perelman School of Medicine, Institute for Immunology, who has expertise in basic and translational cancer immunology. Her research goals are to uncover a novel T cell and immune cell biology paradigm and offer insights on optimizing and tailoring cancer therapies, at the unique intersection of immunology and DNA damage and repair (DDR). She completed her MD in the University of Tokyo, followed by clinical residency. Then she completed her PhD in Immunology at Johns Hopkins University, School of Medicine. Her PhD study revealed that the radiotherapy increased radio-resistant, functionally suppressive regulatory T cells (Treg) in the tumor microenvironment. Taking advantage of her insights from previous radiation oncology research, during her postdoc at the University of Pennsylvania, Perelman School of Medicine, she developed a novel high-dimensional cytometry-based platform that enables simultaneous analysis of DDR and immune markers, especially T cell markers at single cell resolution. She also proposed novel models on the impact of DDR on T cell function and differentiation that underlie the immune responsiveness. She also discovered a novel DDR-Immune signature that can forecast clinical outcome of patients treated with immune checkpoint blockade. Her unique approach and expertise at the intersection of DNA damage and immunology will not only lead to uncover the novel biology of T cells but also mechanism of clinically important problems including resistance to immunotherapy, chemotherapy and radiotherapy and will aid in developing new therapeutic approaches.
Disclosure information not submitted.
Thursday, June 23, 2022
4:00 PM – 4:15 PM PT